BioSpace News Archive

POXEL S.A., a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, announced an update for PXL065 following a positive meeting with the U.S. Food and Drug Administration in the fourth quarter 2019.

QB3 is proud to announce the 2019 cohort of the annual QB3 Biotech/Biopharma Pitch Summit, a group of early-stage companies chosen for their innovative technologies and potential market impact.

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced its financial results for the third quarter ended September 30, 2019 and provided a corporate update.

exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12

Statistically and clinically significant effects on pruritus, xanthomas and growth maintained for up to four years of treatment in Alagille syndrome

NKV-550 Offers a Unique Protective Control®, and Features Gentle Lung® Suite for Clinicians to Protect Patient Lungs

Pivotal trial will study the intravenous administration of the Company’s Trappsol® Cyclo™ drug and will focus on systemic and neurologic outcomes

FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on hematologic, oncologic and metabolic diseases, today announced the presentation of Phase 1 data for FT-4101, the company’s potent, selective fatty acid synthase (FASN) inhibitor in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its third quarter 2019 financial results on Wednesday, November 13, 2019, before the U.S. financial markets open

Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m. CT.